Psyence BioMed targets U.S. push for GMP ibogaine research, manufacturing

Psyence Biomedical Ltd.

Psyence Biomedical Ltd.

PBM

0.00
  • Psyence BioMed launched a U.S. strategic engagement initiative aimed at supporting regulated ibogaine research, with an emphasis on GMP manufacturing and supply readiness.
  • Planning centers on scaling GMP-compliant production capacity to supply future clinical programs, supported by its investment in PsyLabs.
  • Targets include building an ethically sourced, sustainable, traceable ibogaine supply chain designed to support future development and commercialization pathways.
  • Efforts are positioned to align with potential U.S. policy actions that could expand or accelerate authorized scientific and clinical research into ibogaine.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Psyence Biomedical Ltd. published the original content used to generate this news brief on May 16, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.